The packet lists no associated genes, OMIM entries, or inheritance patterns. The causes and genetic basis are therefore unknown in this packet, and no gene or inheritance claims are made here.

The packet contains no diagnostic methods, diagnostic criteria, or GeneReviews diagnosis content, so diagnostic approaches are not described here.

The packet includes one orphan-drug record with status APPROVED: Lytgobi (futibatinib), sponsor Taiho Oncology, Inc., with the indication recorded as treatment of cholangiocarcinoma (CCA). The record does not specify current market status, tumor subtype restrictions, or eligibility, so these details are unknown in this packet. The packet certifies no foundational therapies or GeneReviews management content, so other treatment approaches are not described here.

Prognosis is not certified in this packet. It contains no natural history or survival information, and none is stated here.

ClinicalTrials.gov records in the packet include several studies that name perihilar or hilar cholangiocarcinoma. NCT04993131, titled "Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma" (Oslo University Hospital), is listed as recruiting, with a start date of 2021-09-01 and a completion date of 2045-05-31. NCT07030140, a phase 2 study titled "Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma" (sponsor Jinbo Yue), is listed as recruiting, 2025-07-01 to 2028-01-01. NCT05546372, "Endobiliary Radiofrequency Ablation for Malignant Biliary Obstruction Due to Perihilar Cholangiocarcinoma" (Academisch Medisch Centrum - Universiteit van Amsterdam), is listed as recruiting, 2022-10-22 to 2027-06-30. Some other records are listed as not yet recruiting, and their current status is not verified here. Trial titles do not establish intervention effects.